Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk



Status:Archived
Conditions:Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:June 2009
End Date:December 2015

Use our guide to learn which trials are right for you!

A Biologic Correlates Study for "A Phase 2 Single-Arm Study To Assess The Efficacy and Safety Of 48-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Once a Week for 3 Weeks of a 4-Week Cycle in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-2 or High Ris


This study is under Molecular and Cellular Characterization of Myelodysplastic Syndromes
(MDS) (eProtocol 15369). The purpose of this proposed study is to analyze existing samples
taken from participants participating in a clinical trial evaluating the efficacy and safety
of investigational agent ON 01910.Na (eProtocol 16214). This study will use existing blood
and marrow samples to determine the rate and duration of objective hematologic and marrow
responses, and duration of progression-free survival in ON01910.Na-treated MDS patients.

This study will use existing blood and marrow samples to determine the rate and duration of
objective hematologic and marrow responses, and duration of progression-free survival in
ON01910.Na-treated MDS patients.



We found this trial at
1
site
300 Pasteur Dr
Stanford, California 94305
(650) 723-4000
Stanford university Hospital and Clinics Throughout our history, we have pioneered medical advances that save...
?
mi
from
Stanford, CA
Click here to add this to my saved trials